Environmental nutrient levels impact cancer cell metabolism, resulting in context-dependent gene essentiality 1,2 . Here, using loss-of-function screening based on RNA interference, we show that environmental oxygen levels are a major driver of differential essentiality between in vitro model systems and in vivo tumours. Above the 3-8% oxygen concentration typical of most tissues, we find that cancer cells depend on high levels of the iron-sulfur cluster biosynthetic enzyme NFS1. Mammary or subcutaneous tumours grow despite suppression of NFS1, whereas metastatic or primary lung tumours do not. Consistent with a role in surviving the high oxygen environment of incipient lung tumours, NFS1 lies in a region of genomic amplification present in lung adenocarcinoma and is most highly expressed in well-differentiated adenocarcinomas. NFS1 activity is particularly important for maintaining the ironsulfur co-factors present in multiple cell-essential proteins upon exposure to oxygen compared to other forms of oxidative damage. Furthermore, insufficient iron-sulfur cluster maintenance robustly activates the iron-starvation response and, in combination with inhibition of glutathione biosynthesis, triggers ferroptosis, a nonapoptotic form of cell death. Suppression of NFS1 cooperates with inhibition of cysteine transport to trigger ferroptosis in vitro and slow tumour growth. Therefore, lung adenocarcinomas select for expression of a pathway that confers resistance to high oxygen tension and protects cells from undergoing ferroptosis in response to oxidative damage.
For shRNAs differentially depleted in 3% O 2 , 7.7% scored higher in vivo than in vitro, and 10.5% scored higher in vitro than in vivo, the median score was 0.17. For shRNAs differentially depleted in 21% O 2 , 3.8% scored higher in vivo than in vitro, and 19.6% scored higher in vitro than in vivo, the median score was 0.66. c, Venn diagram of shRNAs with improved viability scores in low O 2 (red) or animals (grey). d, Schematic of the ISC biosynthesis process. e, Fiveday proliferation assay of MDA-MB-231 cells stably transduced with shRNAs targeting NFS1 (shNFS1_1) or RFP (shRFP) as a control. Data are mean ± s.e.m. from three independent biological triplicates. f, Five-day proliferation assay at atmospheric O 2 of MDA-MB-231 stably transduced with either shRFP (R) or shNFS1_1 (N1) and either a vector control (VC), resistant NFS1 cDNA (NFS1res) or catalytically inactive mutant cDNA (NFS1resCD) (top). Data are mean ± s.e.m. from three independent biological replicates. Immunoblots for NFS1 (ribosomal protein S6 (RPS6) included for comparison), images are representative of three replicates (bottom). g, Tumour xenograft weight at 4 weeks, cells transduced as in e but with shRNAs targeting GFP (shGFP) as the control. Data are mean ± s.e.m., n = 25. h, Representative whole mount immunofluorescence of lung lobes (left) and metastasis quantification (right), 6 weeks after tail vein injection with cells transduced as in g. Scale bars, 1 mm. i, Sections from h, tdTomato stain (brown) (left) and quantification of micrometastases per section (right). Scale bars, 100 μ m. Quantification data in h and i are from five independent biological replicates, entire experiment repeated three times with similar results. e-f, P values obtained by heteroscedastic two-sided t-test. NS, not significant.
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those which scored as differentially depleted 1 (Supplementary Table 1 ). shRNAs targeting enzymes catalysing oxygen-consuming reactions (Supplementary Table 2 ) were significantly more likely to be differentially depleted in vivo (Extended Data Fig. 1a, b) .
Oxygen levels affect the activity of oxygen-consuming enzymes, resulting in altered dependence 3 . Because oxygen levels vary considerably between in vivo and in vitro environments 4 , we performed screens at atmospheric (21%) or tissue level oxygen (3%). shRNAs differentially depleted in 21% oxygen (Supplementary Table 3 ) were more likely to be differentially depleted in vitro, resulting in a significantly shifted distribution (median of 0.66 versus 0.17, P < 1 × 10
, Fig. 1b) . Of the 1,384 shRNAs specifically depleted in 21% oxygen, 271 were differentially essential in vitro versus in vivo, a highly significant overlap of 20% (P < 1 × 10 −5
, Fig. 1c and Supplementary Table 4) . Notably, shRNAs targeting the cysteine desulfurase NFS1 were among the most depleted in vitro at 21% oxygen, but exhibited little depletion at 3% oxygen or in vivo, indicative of a specific oxygen-dependent requirement (six out of eight shRNAs scoring, Fig. 1c ).
NFS1 is an essential enzyme in eukaryotes that harvests sulfur from cysteine for the biosynthesis of iron-sulfur clusters (ISCs), protein co-factors sensitive to oxidative damage that are present in at least 48 human enzymes [5] [6] [7] ( Fig. 1d and Supplementary Discussion). Transduction of MCF10DCIS.com or transformed breast cell line MDA-MB-231 with shRNAs targeting NFS1 (shNFS1) reduced protein levels by 80-95% and blocked proliferation in 21% oxygen, an effect reversed at 3% oxygen or in tumour xenografts (Extended Data  Fig. 2a, b) . Indeed, sensitivity to suppression of NFS1 begins at oxygen concentrations above 3-5% ( Fig. 1e and Extended Data Fig. 2c ). To verify that NFS1 dependence requires its catalytic activity, we generated a shRNA-resistant NFS1 cDNA (NFS1res), and modified a predicted catalytic residue (C381, NFS1resCD) 8 . Expression of NFS1res, but not NFS1resCD, completely rescued the proliferative defect induced by shNFS1 ( Fig. 1f and Extended Data Fig. 2d ). ABCB7, which exports ISCs synthesized in mitochondria to the cytosol 9 , also scored as differentially essential in 21% oxygen (three out of five shRNAs scoring, Fig. 1c, d ). Suppression of ABCB7 or other genes required for ISC biosynthesis (ISCU and FXN) impacted proliferation at 21% oxygen without affecting proliferation at 3% oxygen or tumour xenograft growth (Extended Data Fig. 2e, f) , whereas suppression of processes requiring NFS1 for ISC biosynthesis-independent activities 10 did not impact viability (Extended Data Fig. 2g) . Therefore, the oxygendependent sensitivity observed upon NFS1 suppression is a consequence of decreasing ISC biogenesis.
Breast tumours are hypoxic compared to normal breast tissue 11 . However, the oxygen level encountered by a cancer cell seeding a lung metastasis is unknown, and could drive dependence on pathways required under high environmental oxygen. We found that MDA-MB-231 cells expressing tdTomato and either shNFS1 or shGFP control robustly form primary mammary tumours (Fig. 1g) , but shNFS1-expressing cells cannot colonize the lung efficiently, as revealed by analysis of macrometastases ( Fig. 1h and Extended Data Fig. 3a) , micrometastases ( Fig. 1i and Extended Data Fig. 3a-c) , and competition assays (Extended Data Fig. 3d, e) . NFS1 protein levels are increased in cells grown at 21% oxygen versus 3% or 0.5% oxygen in vitro, and Letter reSeArCH in lung metastases compared with primary tumours (Extended Data  Fig. 3f, g ). This regulation of NFS1 protein levels occurs by a posttranscriptional, prolyl hydroxylase-independent mechanism, consistent with a cellular response to high environmental oxygen that involves NFS1 (Extended Data Fig. 3g ). Therefore, breast cancer cells depend upon NFS1 to initiate metastatic lung tumours, which may be due to high environmental oxygen levels.
We next assessed whether NFS1 undergoes genetic alteration in primary human lung cancer. Public datasets reveal increased NFS1 mRNA in lung adenocarcinoma versus normal lung, and in nonsmall-cell lung cancer cell lines versus other lines, in contrast to other core ISC biosynthetic components (Extended Data Fig. 4a, b) . Interestingly, the NFS1 locus is under significant positive selection in non-small-cell lung cancer 12 . The amplification peak contains only two other genes and is present focally in 7.4% of tumours and cell lines, or either focally or non-focally at an overall frequency of 38% (Fig. 2a) . Immunohistochemical analysis revealed that human lung adenocarcinomas exhibited the strongest NFS1 staining followed by squamous cell carcinoma and small-cell lung cancer, which exhibited staining similar to tumour-adjacent normal tissue (Fig. 2b, c) . Within adenocarcinomas, NFS1 staining was heterogeneous: welldifferentiated, low-grade regions and regions of carcinoma in situ exhibited the highest staining, versus poorly differentiated, highgrade regions (Fig. 2b, c) . These data are consistent with increased NFS1 expression in early lung adenocarcinomas at a location or time when cells would have the greatest exposure to the high oxygen environment of the lung. Because 50% of lung adenocarcinoma samples analysed had NFS1 staining similar to amplified lines (NCI-H322, Extended Data Fig. 4c ), multiple mechanisms are likely to exist to upregulate NFS1 expression.
Cell lines harbouring NFS1 amplification (NCI-H322, NCI-H647, and NCI-H2170) had increased levels of NFS1 protein (Fig. 2d) , and expression data show significant correlation between NFS1 mRNA and copy number (Extended Data Fig. 4d ). Transient expression of Streptococcus pyogenes Cas9 and a short guide RNA targeting NFS1 in NCI-H322 cells produced isogenic clones with the loss of many, but not all, of the 7-8 NFS1 copies and NFS1 protein levels similar to non-amplified lines (NCI-H322 crNFS1) (Extended Data Fig. 4e-g ). NCI-H322 crNFS1 cells have impaired proliferation in 21% oxygen and diminished matrix-independent growth, phenotypes reversed by NFS1 re-expression via transduction with NFS1res ( Fig. 2 e-g ), demonstrating that NFS1 amplification drives these phenotypes under atmospheric oxygen.
Because NFS1-amplified human lung cancer lines did not form lung tumour xenografts, we used a KRAS G12D mutant and Trp53 deleted mouse lung cancer line, Kras G12D/+
Trp53
−/− (KP), to assess the requirement for NFS1 in a system with robust NFS1 expression (Extended Data  Fig. 4h) . In vitro suppression of Nfs1 in KP cells by shRNA targeting Nfs1 (shNfs1) reduced Nfs1 protein levels and slowed proliferation in 21%, but not 3%, oxygen (Fig. 2h) . KP cells expressing shNfs1 or shRFP were equally capable of forming subcutaneous tumours, whereas cells expressing shNfs1 instilled intratracheally formed lung tumours poorly (Fig. 2i, j and Extended Data Fig. 4h ). Thus, we conclude that robust NFS1 expression is required for the growth of primary lung tumours.
We next assessed the mechanism by which cancer cells are sensitive to NFS1 suppression. We confirmed the NFS1 requirement persists in VHL-and LKB1 (also known as STK11)-null cells (Extended Data  Fig. 5a ). In low oxygen conditions, metabolism rewires to decrease reliance on oxidative phosphorylation (OXPHOS), a pathway Letter reSeArCH containing many ISC proteins. To assess whether NFS1 dependence results from inhibiting OXPHOS, we used patient-derived cytoplasmic hybrid lines harbouring a deletion in cytochrome b (CYTB), a key complex III component 13 . These cells maintain mitochondrial ISC proteins, but are devoid of respiratory chain activity. Suppression of NFS1 reduced proliferation of CYTB-null cells and wild-type counterparts; proliferation was restored by culture in 3% oxygen (Fig. 3a) . Similarly, supplementation of MDA-MB-231 cells with pyruvate and uridine, which support viability in OXPHOS-deficient cells, did not rescue the proliferative effects of NFS1 suppression (Fig. 3a) . Therefore, the proliferative effects of NFS1 suppression cannot be explained solely by the loss of ISCs from respiratory chain proteins, indicating that NFS1 suppression has effects that extend beyond OXPHOS and the electron transport chain. Indeed, analysis of CRISPR-Cas9 genetic screening datasets reveals several cell-essential ISC proteins (Extended Data Fig. 5b ).
Atmospheric oxygen is toxic to cells with defects in management of reactive oxygen species (ROS) 14, 15 . However, the antiproliferative effects of NFS1 suppression are not affected by antioxidant treatment, and levels of the antioxidant glutathione are not decreased (Fig. 3b and Extended Data Fig. 5c, d ). NFS1 suppression does not increase cytoplasmic ROS, in contrast to the suppression of the cytosolic or mitochondrial superoxide dismutases (SOD1 or SOD2, respectively), and 3% oxygen culture only partially rescues the antiproliferative effects of SOD1 and SOD2 (Extended Data Fig. 5e , f), consistent with a specific effect of oxygen on ISCs. These data do not support the hypothesis that sensitivity to NFS1 suppression in high oxygen is due to ROS induction.
ISCs undergo degradation upon exposure to oxygen and other oxidants in biochemical assays 16 (Supplementary Discussion). We assessed ISC turnover in ACO1 by monitoring cytoplasmic aconitase activity, and OXPHOS components by monitoring oxygen consumption. We also monitored the iron-starvation response, activated by loss of the ACO1 ISC, the apo form of which functions as an iron-responsive protein (IRP1), stabilizing transferrin receptor 1 (TFRC) mRNA and inhibiting translation of ferritin heavy chain (FTH1) 17 . NFS1 suppression induced TFRC expression and repressed FTH1 and cytoplasmic aconitase activity, phenotypes rescued by NFS1res expression (Fig. 3c, d and Extended Data Fig. 5g ), consistent with previous work on IRP1 mRNA binding 18 . NFS1 suppression did not affect oxygen consumption of cells cultured in 3% oxygen, but markedly reduced oxygen consumption in cells grown at 21% oxygen (Fig. 3e) . NFS1 suppression and culture in 21% oxygen had an additive effect on cytosolic aconitase activity (Fig. 3f) . This fine-tuned modulation of ISC occupancy in IRP1 is consistent with its role as an iron or ISC sensor.
These results highlight the sensitivity of ISCs to oxygen, leading us to investigate sensitivity to ROS. Culture at 21% oxygen does not increase ROS levels (Fig. 3g) , whereas aconitase activity is reduced (Fig. 3f) and TFRC expression is increased (Fig. 3h) . By contrast, treatment with tert-butyl hydroperoxide (tbHP) increases ROS levels without affecting aconitase activity or TFRC expression in NFS1-suppressed or control cells (Fig. 3f-h ). Therefore, oxygen and tbHP have divergent effects on ROS levels and ISC proteins. Indeed, levels of mitochondrial ROS are increased in 0.5% oxygen 19 , yet cells expressing an NFS1 shRNA proliferate well in this condition (Fig. 1e) . These results support a model in which oxygen present in the cell routinely encounters and oxidizes ISCs, whereas ROS encounter cellular antioxidant defences and are neutralized. Therefore, NFS1 suppression results in proliferative arrest upon exposure to atmospheric oxygen because the ISC biosynthetic machinery cannot meet the increased demand caused by specific damage to ISCs by oxygen, leading to the loss of ISCs from essential proteins (Fig. 3i) .
Although treatment with tbHP does not impact ISC protein activity (Fig. 3f, h ), surprisingly we observed that NFS1 suppression sensitizes MDA-MB-231 cells to tbHP, agents that induce mitochondrial ROS (paraquat) or inhibit glutathione biosynthesis (buthionine sulfoximine, BSO), but not to compounds (etoposide and doxorubicin) that inhibit growth by other mechanisms (Fig. 4a and Extended Data Fig. 6a, b) . Therefore, a downstream consequence of NFS1 suppression is likely to be responsible for increased ROS sensitivity, rather than further damage to ISCs. Indeed, NFS1 suppression blocks proliferation at 21% oxygen, whereas addition of ROS-inducing compounds at 3% oxygen ostensibly Letter reSeArCH results in cell death. Because NFS1 suppression robustly activates the iron-starvation response (Fig. 3c, h) , we assessed the effect of activating this pathway on ROS-induced cell death.
Iron promotes the production of superoxide radicals via the Fenton reaction, which can result in lipid peroxidation 20 . Ferroptosis, a form of cell death, has been characterized by iron accumulation and cytoplasmic and lipid ROS induction 21 . Erastin, a ferroptosis inducer, can inhibit cystine import, and depresses glutathione levels 22 . Consistent with erastin inducing iron accumulation via inhibition of ISC biosynthesis, erastin treatment activated the iron-starvation response, although the effect of NFS1 suppression was far more robust (Extended Data Fig. 6c) . However, NFS1 suppression alone cannot induce ferroptosis because NFS1 suppression does not decrease glutathione levels or increase ROS. Furthermore, ferrostatin (Fer-1), iron chelators, suppression of lysosomal acidification, and antioxidants do not rescue the proliferation defect caused by NFS1 suppression, despite being suppressors of ferroptosis 23 ( Fig. 3b, g and Extended Data Fig. 5c-e) . We therefore hypothesized that induction of the iron-starvation response upon NFS1 suppression promotes ferroptosis when cells encounter ROS. Indeed, cell death induced by BSO or tbHP treatment of NFS1 suppressed cells is rescued by iron chelators and Fer-1, but not by inhibitors of apoptosis, necrosis, or autophagy ( Fig. 4b and Extended Data Fig. 6b, d ). Moreover, in cells expressing shNFS1 and treated with BSO, tbHP, or erastin, cellular and lipid ROS increased, phenotypes rescued by Fer-1 (Fig. 4c, d and Extended Data Fig. 6e-h ).
Although some cell lines respond to erastin by undergoing ferroptosis in under 24 h, many exhibit relative resistance 22 . Erastin treatment of four lines (MDA-MB-231, A549, NCI-H838, or NCI-H460), resulted in widespread cell death specifically in NFS1 suppressed cells (Fig. 4b, e and Extended Data Fig. 6i ). Cystine deprivation and inhibition of a downstream target of erastin, GPX4, also cooperate with NFS1 suppression to induce cell death (Extended Data Fig. 6j, k) . We then evaluated two recently described methods for inducing oxidative stress in vivo: treatment with cyst(e)inase, a cyst(e)ine-degrading enzyme 24 , or a combination of cystine transport inhibitor sulfasalazine (SSA) and BSO 25 . MDA-MB-231 tumour xenografts expressing an NFS1 shRNA are specifically sensitive to cyst(e)inase, with tumours initially regressing (range, 5-65%; median, 21 ± 8% (s.e.m.)) before resuming growth (Fig. 4f) . Tumours in this group exhibited NFS1 re-expression, consistent with NFS1 conferring resistance to treatment (Extended Data Fig. 7a, b) . Combined administration of SSA and BSO generally impacts tumour growth, but tumours expressing an NFS1 shRNA exhibit additional toxicity (Extended Data Fig. 7c) . Therefore, inhibition of ISC biosynthesis promotes induction of ferroptosis in vitro, and sensitizes cells to oxidative stress in vivo (Fig. 4g) . In summary, although atmospheric oxygen and cystine transport inhibitors both increase the iron-starvation response, suppression of NFS1 does so to a much greater extent. These observations lead to the hypothesis that one can trick cancer cells into taking up large quantities of iron and releasing intracellular iron stores via modulation of NFS1 or downstream effectors, such as IRPs, leaving them at increased risk of ROSmediated cell death mechanisms such as ferroptosis.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. The TRC numbers for the shRNAs used are: shRFP, TRCN0000072203; shGFP, TRCN0000072186; shNFS1_1, TRCN0000229753; shNFS1_2, TRCN0000229755; shABCB7_1, TRCN0000059355; shABCB7_2, TRCN0000059356; shSOD1, TRCN0000018344; shSOD2, TRCN0000005943; shISCU, TRCN0000289988; shFXN_1, TRCN0000006138; shFXN_2, TRCN0000006137; MOCS3_1, TRCN0000045642; MOCS3_2, TRCN0000045640. The shRNAs used for the mini-screen targeting NFS1 are shNFS1_1, shNFS1_2, TRCN0000229756, and TRCN0000180881, with control shRNAs shRFP, shGFP, TRCN0000072208, TRCN0000072210, TRCN0000072225, and TRCN0000072236. The shRNA targeting mouse Nfs1 was cloned into the TRC pLKO.1P vector using the following o li go nu cl eo tidess: C CG GA GA AC AC CA AG TT GT AT TA AA CT CG AG TT TA AT A C AACTTGGTGTTCTTTTTTG and A AT TCAAAAAAGAACACCAAGTTGT ATTAAACTCGAGTTTAATACAACTTGGTGTTCT.
All individual pLKO.1 shRNA plasmids and expression vectors used in this study are deposited at Addgene (https://www.addgene.org) for distribution. Cell culture. Cells were tested for the presence of mycoplasma by PCR-based methods and the authenticity of cell lines not ordered and used within one year was verified by STR profiling (Duke University). Cells were cultured in RPMI supplemented with 10% IFS (Sigma) and penicillin and streptomycin, except MCF10DCIS.com cells, which were cultured in 50:50 DMEM and F12 media with 5% horse serum (Invitrogen) and penicillin and streptomycin. O 2 concentration was controlled by placing cells in a hypoxic incubator (InVivo 2 400, Baker; or HeraCell 150i, Thermo Fisher). Cells were equilibrated to the O 2 concentration indicated in each panel for at least 5 days unless otherwise stated. To generate clones in which the copy number of the NFS1 locus was reduced, we transiently expressed S. pyogenes Cas9 and a single guide RNA targeting the NFS1 genomic locus (target sequence GCGGATTTGCAGTTCCAGAA cloned into pLENTIC-RISPR) in NCI-H322 cells, and obtained clones derived from single cells (NCI-H322 crNFS1). Several clones exhibited a decrease in NFS1 protein to a level similar to non-amplified cell lines, consistent with loss of many, but not all, of the 7-8 NFS1 copies as verified by Sanger sequencing (Extended Data Fig. 4e-g ). Analysis of metabolic enzymes by reaction performed. Reactants and products for metabolic enzyme reactions were extracted from the UniProt database. Those enzymes whose chemical reactions were not found in UniProt were curated manually from available databases and publications. The 25 most highly used metabolites were selected for analysis and the number of scoring shRNAs computed. Significance was assigned on the basis of a Fisher's exact test comparing these data to the number of scoring shRNAs for all other enzymes for which a reaction had been annotated. Pooled shRNA screening. In vivo shRNA screening was performed as described 26 using a previously published shRNA library 1 (sequences provided in Supplementary Table 1 ). In brief, MCF10DCIS.com cells were infected with shRNAs in groups of 28 functional pools and selected for 3 days with 0.5 μ g ml −1 puromycin, followed by withdrawal of puromycin for 2 days. For the in vivo screen, 500,000 cells in 33% growth factor-reduced matrigel were injected into the fourth mouse mammary fat pad of NOD.CB17 Scid/J mice and tumours were harvested 4 weeks after implantation. At the same time, cells were cultured in vitro and harvested for the in vitro screen after 4 weeks. For the high versus low O 2 comparison, a second in vitro screen was performed in the same fashion except that cells were cultured at 21% O 2 or 3% O 2 in a single pool. In vivo screens were performed in replicates of 8-12 tumours, and in vitro screens were in replicates of four. Pool deconvolution and calculation of log 2 fold change scores were performed as described 1 . To combine data across multiple pools, the median shRNA log 2 fold change scores of the control shRNAs for each pool was normalized to 0. For differential essentiality, a log 2 fold change cut-off of ± 2 was used. The mini-screen was conducted using the same protocol except MDA-MB-231 cells were used with a pool of 4 shRNAs targeting NFS1 and 6 non-targeting controls. In addition to cells in culture and orthotopic tumours, lungs were also harvested for genomic DNA and processed together with the other samples. Average log 2 fold change values are reported for each shRNA and normalized to the difference observed in 3% O 2 .
For competition assays involving two shRNAs, genomic DNA was harvested and the region containing the shRNAs was amplified and sequenced by Sanger sequencing. The relative abundance of each shRNA was calculated by measuring the proportion of shRFP or shNFS1_1 signal at the first six nucleotide positions that differ between the two shRNAs, and taking the average. Cell proliferation and viability assays. Cells were plated at 25,000 cells per well in a six-well dish and infected with lentiviral shRNAs at a multiplicity of infection of 2.5 in 1 μ g ml −1 polybrene by 30 min spin infection at 1,178g in Beckman Coulter Allegra X-12R centrifuge with an SX4750 rotor and Microplate Carrier attachment followed by an overnight incubation, 1 μ g ml −1 puromycin selection for three days, and one day recovery without puromycin. Cells were then plated out at 25,000 per well in triplicate and counted three days later, or protein harvested for western blotting or qPCR analysis. Cells were moved to the indicated O 2 conditions after spin infection. Viability assays were carried out by plating 1,000-2,000 cells in replicates of four in 96-well clear bottom plates (Greiner 655098) one day before adding the indicated drug. Viability was assessed four days after drug treatment by Cell Titer Glo (Promega) and normalized to an untreated control. Soft agar assay was performed in 6-cm dishes by plating 100,000 cells in 0.4% noble agar (Sigma) in RPMI on a bed of 0.6% noble agar in RPMI. Colonies were counted after 3-4 weeks of growth by imaging plates at low magnification using a dissecting microscope (Leica M165), colony size and number were analysed using CellProfiler software 27 .
Immunoblotting and immunohistochemistry.
Immunoblotting was performed by washing cells in cold PBS followed by addition of lysis buffer (50 mM Tris pH 7.4, 150 mM NaCl, 1% NP-40, 0.1% sodium deoxycholate, 0.1% SDS, 2 mM EDTA) containing a protease inhibitor cocktail (Roche). Lysates were incubated on ice for 10 min and cleared by centrifugation at 21,000g for 10 min. Protein levels were quantified using a BCA protein assay kit (Pierce) and 15 μ g protein was loaded onto Bolt 4-12% Bis-Tris polyacrylamide gels (Thermo Fisher), electrophoresed at 100 V for 2 h, and transferred in transfer buffer (2.2 g l −1 CAPS, 0.45 g l −1 NaOH, 10% ethanol) to a PVDF membrane (Millipore IPVH00010) at 40 V for 2 h. Metastatic foci were counted from RFP stained sections by a blinded researcher.
For RFP and tdTomato immunohistochemistry, deparaffinization and staining were carried out on a Ventana XT using a DISCOVERY DAB Map Detection Kit. Slides were treated with Protease 3 for 12 min, antibody was applied at a 1:1,600 dilution and incubated for 60 min, secondary antibody (Vector BA-1000) was applied at a 1:200 dilution and incubated for 30 min. For NFS1 immunohistochemistry, deparaffinization and staining was carried out on a Ventana XT using a DISCOVERY ChromoMap DAB Kit. Slides were treated with CC1S (Tris-based buffer antigen retrieval for 36 min). Primary antibody was applied at a 1:100 dilution and incubated for 3 h. Secondary antibody (DISCOVERY OmniMap anti-Ms HRP) was applied neat for 8 min. All slides were haematoxylin counterstained following the IHC assay. For comparisons of NFS1 level in primary tumour and lung metastases, formalin-fixed paraffin-embedded tissue was cut fresh and compared side-by-side on the same slide. Cultured cells expressing high (NCI-H322) and low (MDA-MB-231) levels of NFS1 were used to calibrate the dynamic window of staining intensity. Cultured cells were processed in conditions used to mimic formalin fixation and paraffin embedding, by plasma-thrombin embedding and sectioning. NFS1 H-score was scored by a blinded pathologist on a standard 0-300 point scale based on NFS1 mitochondrial staining intensity and area. Human studies were approved by the NYU School of Medicine Institutional Review Board. O 2 consumption assays. O 2 consumption was measured using the Seahorse Extracellular Flux Analyzer (XFe24). Cells were seeded at 35,000 per well on the day before measurement and the assay was conducted in Seahorse media with 10 mM glucose and 1 mM glutamine. At the indicated time points FCCP (1 μ M) or antimycin (1 μ M) were added. For experiments conducted at 3% O 2 , cells were infected, selected in puromycin, and plated on Seahorse plates in 3% O 2 ; however, the O 2 consumption measurements themselves were conducted at ambient O 2 conditions. Letter reSeArCH qPCR. RNA was isolated by column purification (RNeasy Kit, Qiagen) and cDNA synthesis was performed by reverse transcription of 1 μ g of total RNA by reverse transcriptase (Superscript III, 18080044, Invitrogen) in a reaction containing 1 μ l RNase OUT (10777019, Invitrogen). qPCR was performed on cDNA using SYBR green quantification (Maxima qPCR master mix, K0222, Thermo Fisher). ABCB7, ISCU and FXN expression was quantified relative to ACTB, MOCS3, NFS1, ENO2, and SLC2A3 were quantified relative to RPL13A using the following primers: ABCB7 forward: GCAGTCACACGGTGGAGAACT, ABCB7 reverse: TTGACCAAAGTTCAGCATAGCC; ACTB forward: AAGGGACTTCC TGTAACAATGCA, ACTB reverse: CTGGAACGGTGAAGGTGACA; ISCU forward: CCAGCATGTGGTGACGTAATG, ISCU reverse: AGCTCCTTGGCG ATATCTGTG; FXN forward: CTTGCAGACAAGCCATACACG, FXN reverse: ACACCCAGTTTTTCCCAGTCC; NFS1 forward: CACTCCCGGACACA TGCTTAT, NFS1 reverse: TGTCTGGGTGGTGATCAAGTG; SLC2A3 forward: AGTCATGATCCCAGCGAGAC, SLC2A3 reverse: GCCGATTGTAGCAA CTGTGA; ENO2 forward: AGCTGGCCATGCAGGAGTTC, ENO2 reverse: GGCTTCCTTCACCAGCTCCA; MOCS3 forward: CGCTCCCTGCAAC TACTGA, MO CS3 reverse: CAGTCGCT TATAGTCGGTGACA; RPL13A forward: CATAGGAAGCTGGGAGCAAG, RPL13A reverse: GCCCTCCAATCAGTCTTCTG Analysis of NFS1 copy number and expression. Copy number data shown in Fig. 2a were downloaded from the Broad Institute Tumorscape website (http:// www.broadinstitute.org/tumorscape/pages/portalHome.jsf) and contain both cell line and primary tumour data. The minimum amplified region reported in Fig. 2a was identified from the website Broad TCGA website (https://www.broadinstitute.org/tcga/home) using the '2015-06-01 stddata__2015_04_02 regular peel-off ' analysis version and the previously analysed 'lung adenocarcinoma' cancer subset Following staining, cells were washed with PBS, trypsinized, and collected in 500 μ l of PBS. For tbHP experiments, cells were washed twice, stained with the indicated probes, treated with tbHP in serum-containing media for 4 h, washed again, trypsinized, and collected. For experiments performed at 3% O 2 , cells were equilibrated for 1 week before assessing ROS level. Flow cytometry data were collected on an Attune NxT Flow Cytometer with an excitation wavelength of 488 nm using the BL1 collection channel. Analysis of data was performed using FlowJo v.10 software. Aconitase assay. Aconitase activity was measured using an Aconitase Assay Kit (Sigma, MAK051). For each condition, 600,000 MCF10DCIS.com cells were plated in a 5-cm plate. The next day cells were washed with PBS and harvested by trypsinization. To determine the aconitase activity of harvested cells, the manufacturer's protocol was followed without the addition of the activating solution. Figure 3d uses six control (shCON) and four NFS1-targeting shRNAs in small pools in MDA-MB-231 cells. Transduced cell pools were grown at 21% O 2 or 3% O 2 in vitro, or injected orthotopically into the mammary fat pad and allowed to form primary tumours and lung metastases. Cells, primary tumours, and lungs were harvested 6 weeks after initiation of in vitro cultures or tumours, and isolated DNA was subjected to deep sequencing. Differential abundance of each shRNA is reported relative to the 3% O 2 condition for samples grown in the indicated O 2 concentrations, primary tumours, or lungs derived from mice harbouring these tumours after 6 weeks. Competition assay as reported in Extended Data Figure 3e uses MDA-MB-231 cells expressing a control vector or NFS1res, and subsequently transduced with either shRFP or shNFS1_1. Equal numbers of cells transduced with shRFP or shNFS1_1 were mixed before tail vein injection, and the relative abundance of each shRNA in both groups are reported relative to NFS1res.
Competition Assays. Competition assay as reported in Extended Data
Animal experiments. Tumours were initiated in 4-8-week-old female NOD. CB17 Scid/J mice. Orthotopically in the mouse mammary gland, by implantation of 500,000 cells in 25 μ l 33% Matrigel into the fourth mouse mammary fat pad; subcutaneously, by injection of 500,000 cells in 100 μ l 33% Matrigel into the left or right flank of the mouse; via tail vein by injection of 500,000 cells in 150 μ l RPMI into the mouse tail vein; and via intratracheal instillation by instilling 200,000 cells in 50 μ l 2 mM EDTA as described 31 . Cancer cells were transduced with viral shRNAs, selected for 3 days with puromycin, and allowed to recover for one day before introduction into mice. For experiments comparing subcutaneous and lung tumour formation, shRNA transduced cells were prepared at the same time and injected on the same day. Animals were imaged by IVIS (Perkin Elmer) 15 min following injection subcutaneously into the neck scruff with XenoLight d-Luciferin (165 mg per kg body weight, Perkin Elmer). Average luminescence was quantified per mouse from equal sized bins covering the mouse thorax. For experiments in which tumour growth was measured upon drug treatment, MDA-MB-231 cells, implanted as described above, were allowed to form palpable tumours (~ 4 mm diameter) and mice were sorted into treatment groups as described below. PEG-Cyst(e)inase was delivered via intraperitoneal injection at 50 mg per kg body weight every 3 days, SSA was delivered by daily intraperitoneal injection at 250 mg per kg body weight, and BSO was delivered in the drinking water at 20 mM with 5 mg ml −1 sucralose. Tumours were measured by caliper and tumour volume calculated by 0.5 × length × weight 2 . Lungs were fixed by slow infusion with 10% formalin before paraffin embedding and sectioning. Whole-mount lung images were captured using a fluorescent dissecting microscope (Leica M165) and lung foci were quantified by a blinded researcher. All experiments involving mice were carried out with approval from the Committee for Animal Care and under supervision of the Department of Comparative Medicine at MIT and NYU Langone Medical Center. The maximal tumour volume permitted is 2 cm 3 and in none of the experiments were these limits exceeded. Statistical analysis. Experiments were repeated at least three times in the laboratory with the following exceptions, the RNAi screen and deep sequencing based competition assays (Fig. 1a-b and Extended Data Fig. 1 c, d ), immunohisto chemical staining of NFS1 in human/mouse tissue (Fig. 2b, c and Extended Data Fig. 4) , and effects of cyst(e)inase or SSA/BSO on tumour growth (Fig. 4) , which were performed once. t-tests were heteroscedastic to allow for unequal variance and distributions assumed to follow a Student's t distribution, and these assumptions are not contradicted by the data. No samples or animals were excluded from analysis, sample size estimates were not used, and replicate measurements were taken from distinct samples. To study the effects of cyst(e)inase or SSA/BSO on tumour growth, animals were randomly assigned into a treatment group with the constraint that the starting tumour burden in the treatment and control groups were similar. Studies were not conducted blinded except as otherwise noted above (analysis of the number of metastatic foci, immunohistochemical analysis of NFS1 levels in human tissue). Data availability. The data that support the findings of this study are available from the corresponding authors upon reasonable request. 
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Extended Data Figure 1 | Analysis of screening results by reaction reactants and products. a, Histogram of shRNA depletion scores. shRNAs (11, 370) were scored based on their differential abundance in the in vitro and in vivo screens. shRNAs were further subdivided into those which targeted enzymes that consume O 2 (red, 1,035 shRNAs) and to those targeting other genes (black, 10,335 shRNAs). Bin size = 1 log 2 fold change unit with the upper end of the range indicated on the x axis. The shRNAs in the shaded region are scored, and the percentage of these shRNAs falling in the indicated categories and the median of the entire distribution are reported. b, Enzymes were classified based on whether they catalysed reactions involving specific metabolites, and the most commonly used 25 metabolites are reported. The number of shRNAs differentially depleted in vivo versus in vitro with a log 2 fold change cut-off > 2 are reported (scoring shRNAs), as are the total number of shRNAs targeting enzymes in each category. . ABCB7 mRNA levels normalized to ACTB mRNA and relative to shRFP, (right). Data are from three independent biological replicates. f, Five-day proliferation assays of MCF10DCIS.com cells upon introduction of shRFP (black) or shRNAs targeting FXN (shFXN_1 or shFXN_2, grey) or ISCU (shISCU, blue) at the indicated O 2 concentrations or upon addition of the antioxidant trolox (100 μ M). Data are from three independent biological triplicates (left). FXN or ISCU mRNA levels normalized to ACTB mRNA and relative to shRFP (right). g, Proliferation assay (left, data from three independent biological triplicates) and mRNA levels (right, data from three independent biological replicates) as in d upon introduction of RFP (shRFP, black), or shRNAs targeting MOCS3 (shMOCS3_1 or shMOCS3_2). MOCS3 is an enzyme essential for molybdenum co-factor biosynthesis, a process in which NFS1 has been proposed to play a critical role independent of ISC biosynthesis Life Sciences Reporting Summary Nature Research wishes to improve the reproducibility of the work that we publish. This form is intended for publication with all accepted life science papers and provides structure for consistency and transparency in reporting. Every life science submission will use this form; some list items might not apply to an individual manuscript, but all fields must be completed for clarity.
For further information on the points included in this form, see Reporting Life Sciences Research. For further information on Nature Research policies, including our data availability policy, see Authors & Referees and the Editorial Policy Checklist.
Experimental design 1. Sample size
Describe how sample size was determined.
No statistical methods were used to predetermine samples sizes.
Data exclusions
Describe any data exclusions. None
Replication
Describe whether the experimental findings were reliably reproduced.
Experiments were repeated at least three times in the laboratory with the following exceptions, the RNAi screen and deep sequencing based competition assays ( Fig. 1a-b , Extended Data Figure 1 c,d ), immunohistochemical staining of NFS1 in human/mouse tissue (Fig 2b,c, Extended Data Fig. 4) , and effects of cyst(e)inase or SSA/BSO on tumour growth (Fig. 4) , which were performed once.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
To study the effects of cyst(e)inase or SSA/BSO on tumour growth, animals were randomly assigned into a treatment group with the constraint that the starting tumour burden in the treatment and control groups were similar.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
Studies were not conducted blind except analysis of the number of metastatic foci and immunohistochemical analysis of NFS1 levels in human tissue.
Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
